Blockchain Registration Transaction Record
Quantum BioPharma Advances MS Drug Lucid-MS, Targets Demyelination
Quantum BioPharma (NASDAQ: QNTM) advances MS drug Lucid-MS targeting demyelination, completes Phase 1, enters IND stage for Phase 2. Diversified portfolio includes unbuzzd(TM) wellness product. Learn more.
This news matters because Quantum BioPharma's focus on demyelination in multiple sclerosis offers a novel therapeutic approach that could address the root cause of disability progression, potentially improving outcomes for millions of MS patients worldwide. The company's diversified portfolio also provides multiple pathways to revenue, which may enhance its financial stability and long-term growth prospects.
| Blockchain | Details |
|---|---|
| Contract Address | 0xeA2912a8DA1CD48401b10cB283585874d98098F4 |
| Transaction ID | 0xc910e3aa1b559b4ae2462a01e0d12aa94ff11e3c5da459fe3d1da2b0250193e4 |
| Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
| Chain | polygon-main |
| NewsRamp Digital Fingerprint | faceLsRa-fd3ca541897698af3bd47992a3a919c2 |